logo
PricingOpen Demat Account at ₹0 AMCBecome a PartnerCustomer ServiceDhan SupportDhan Blog
fuzz
Logo
MadeForTrade CommunityIndicator by Dhan
Home
InvestmentsIPOHimalaya Nutravedics IPO

Himalaya Nutravedics IPO

SME

Open Date

22 Sep 2026

Close Date

24 Sep 2026

Min Investment

₹ 2,40,000

Lot Size

1,200

Issue Size

₹ 26.50 Cr

Price Range

₹ 100 - ₹ 106

Subscribed

-
Pre-Apply Now
status

This IPO is Open for Pre Apply.

IPO Timeline
check
IPO Offer Start
22 Sep 2026
check
IPO Offer Ends
24 Sep 2026
check
Allotment Finalisation
25 Sep 2026
check
Refund Initialisation
28 Sep 2026
check
Non-Institutional Buyers (sHNI)
28 Sep 2026
check
Listing of Shares
29 Sep 2026
IPO Subscription Details as on 22 Sep 2026, 08:32 AM

No Subcription Details for this IPO

IPO subscription details, if any,
will appear here

Note: This information is provided for general guidance only. Dates may be subject to change.
border
About the Company
Himalaya Nutravedics India Limited is a Hyderabad-based manufacturer, marketer, and distributor of Ayurvedic and Nutraceutical formulations, operating through a hybrid business model comprising own-brand products (classical Ayurvedic, proprietary Ayurvedic, and nutraceutical supplements) and third-party contract manufacturing. The company operates a single WHO-GMP, ISO 9001:2015, and ISO 22000:2018 certified integrated facility in Cherlapally, Hyderabad, capable of producing softgels, tablets, medicated oils, liquid orals, and hardgel capsules. Revenue from operations grew from ₹1,442.56 lakhs in FY2024 to ₹4,306.75 lakhs in FY2026, with PAT rising to ₹738.97 lakhs, reflecting a shift toward higher-margin branded business (51.14% of FY2026 revenues). The company follows a doctor-centric, offline distribution model across 17 states, supported by ~58 sales personnel and a stockist-driven network, with strategic plans to expand pan-India, diversify its product portfolio, and explore export markets.
rocket

Founded In

2022

rocket

CEO

-

Financials of Himalaya Nutravedics India IPO

Income Statement
Balance Sheet
Cash Flows
Total Income
Total Expenses
Total Profit
Key Performance IndicatorsMar 2024Mar 2025Mar 2026
Operating Revenue14.4321.0043.07
Other Income0.000.000.05
Total Income
14.4321.0043.12
Total Expenses
13.8318.7535.64
Profit Before Tax0.592.257.48
Total Profit
0.432.237.39

All figures are in crores (₹)

border

Utilisation of Proceeds

All figures are in crores (₹)

PurposeAmount
The company proposes to utilise a portion of the Net Proceeds towards funding its working capital requirements in the ordinary course of business and to accelerate its strategic expansion into Direct-to-Consumer (D2C) segments, supporting higher inventory levels, receivable cycles, and fulfilment requirements.14
The company proposes to utilise a portion of the Net Proceeds towards branding, digital marketing, and sales expansion initiatives, including advertising on e-commerce and quick commerce marketplaces, development of a proprietary D2C website, and performance marketing campaigns for customer acquisition.8
The company intends to deploy the balance Net Proceeds for general corporate purposes, including strategic initiatives, strengthening marketing network and capability, brand building, meeting business exigencies, salaries, and ordinary course of business expenses, subject to applicable regulatory limits.-
border
  • Integrated Multi-Dosage Manufacturing Capability: The company operates an integrated manufacturing facility capable of producing medicated oils, soft gelatin capsules, hard gelatin capsules, tablets, and liquid orals, enabling product development across multiple formats without reliance on external manufacturers.
  • Doctor Acceptance Supported by Product Performance Rather Than Mass Advertising: The company's formulations have achieved repeat prescriptions through scientific detailing, CME programmes, and medical camps, allowing marketing cost control with marketing expenses at only 4.16% of total revenue in FY2025-26.
  • Long-Standing Relationships with Suppliers and Customers: The company maintains repeat customer engagements, with the top 10 customers contributing 81.24% (₹3,498.75 Lakhs) of revenue from operations in FY2025-26, reflecting strong supply reliability and product acceptance.
  • Geographic Expansion Achieved Over a Relatively Short Operating History: Since commencing operations in September 2022, the company has expanded its branded business presence across 17 states within approximately three years, aligning with India's nutraceuticals market projected to grow at a CAGR of 13.6–15.9% through 2030.
  • Broad Therapeutic Coverage Across Ayurvedic and Nutraceutical Segments: The company's product portfolio spans multiple therapeutic categories including gut health, cardiac and metabolic wellness, diabetes management, pain management, immunity, and infertility, enabling cross-selling across diverse prescribing needs.

Open IPOs for Subscription

No Open IPOs

Stay tuned, there will be more IPOs listing soon!


fuzz

Listed IPOs

No Listed IPOs

Stay tuned, there will be more IPOs listing soon!


Invest & Trade with a Trading
Platform That's #MadeForTrade

Open your Dhan Account in minutes!
border

Explore  |  Sitemap

*All securities mentioned on this website are exemplary and not recommendatory.

*Current prices on the website are delayed by 15 mins, login to check live prices.

We are bullish on India, we are bullish on India's prospects to be one of the largest economies in the world. We believe that the stock market provides a unique opportunity for all of India's traders and investors to participate in the growth story of the country.

Yet, most investing & trading platforms in India have remained more or less the same over the past decade. Times have changed and retail traders and investors have become smarter about managing their trades and money. Modern traders & investors require an online trading platform that helps them keep up with the technological advancements of our time.

That's why we're building Dhan - to help you trade, to help you invest, and to help you participate in India's growth stock via the stock market with awesome features and an incredible experience.

©2021-2026 Raise Securities Private Limited (formerly Moneylicious Securities Private Limited). All rights reserved. CIN: U74999MH2012PTC433549 Raise Securities is part of Raise Financial Services and works closely with Raise Partners across services.

SEBI Stock Broker Registration No: INZ000006031 | Depository Participant (CDSL) ID: IN-DP-289-2016 | SEBI Research Analyst Registration No: INH000023357
Exchange Membership No. : NSE: 90133 | BSE: 6593 | MCX: 56320
Registered & Corporate Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai – 400104, Customer Care: 9987761000.


For any query / feedback / clarifications, email at help@dhan.co.

In case of grievances for any of the services rendered by Raise Securities Private Limited, please write to grievance@dhan.co (for NSE, BSE and MCX) or grievancedp@dhan.co (for Depository Participant). Please ensure that you carefully read the Risk Disclosure Document as prescribed by SEBI, our Terms of Use and Privacy Policy. Compliance Officer: Mr. Manish Garg and Mobile: 8655740961 Email: complianceofficer@dhan.co To lodge your complaints using SEBI SCORES, click here.


Disclaimer: All communications with the client via chat, phone, or email are for support purposes only. Any commitments or statements made by the agent (human or virtual) shall not be binding on the company.


DHAN is a brand owned by Raise Securities Private Limited. All DHAN clients are registered under Raise Securities Private Limited. Clients are advised to refer to our company as Raise Securities Private Limited when communicating with regulatory authorities.


Procedure to file a complaint on SEBI SCORES/SMART ODR Portal: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances. You may refer the website https://scores.sebi.gov.in/ for more information. You may also download the SEBI Scores app to log a complaint Android: https://play.google.com store apps sebiscores iOS: https://apps.apple.com app sebiscores.


Disclaimer: Investment in the securities market are subject to market risks, read all the related documents carefully before investing. Brokerage will not exceed the SEBI prescribed limit


Attention investors:

  1. Stock brokers can accept securities as margins from clients only by way of pledge in the depository system w.e.f September 01, 2020.
  2. Update your e-mail and phone number with your stock broker / depository participant and receive OTP directly from depository on your e-mail and/or mobile number to create pledge.
  3. Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month.

Note: As a policy we do not give stock tips or recommendations and have not authorized anyone to give this on behalf of us. If you know anyone claiming to be a part of Dhan / / Raise or our associate companies or partners and offering such services, please report us on help@dhan.co. Important Information for Investors: To prevent unauthorized transactions in your trading / demat account, do not share your account details, credentials or any personal details with anyone. Keep your mobile number updated with your Stock Broker, Depository Participant and ensure that the same is registered with Stock Exchanges, Depository and KRAs. You will receive alerts and information on your registered mobile number / email for debit and other important transactions in your demat account directly from CDSL / Exchange on the same day. KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Stock Broker, DP, Mutual Fund, etc.), you need not undergo the same process again when you approach another intermediary. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account. This is issued in the interest of investors.


Investors should be cautious on unsolicited emails and SMS advising to buy, sell or hold securities and trade only on the basis of informed decision. Investors are advised to invest after conducting appropriate analysis of respective companies and not to blindly follow unfounded rumours, tips etc. Further, you are also requested to share your knowledge or evidence of systemic wrongdoing, potential frauds or unethical behaviour through the anonymous portal facility provided on BSE & NSE website. Issued in the interest of the investors.


Raise Securities Private Limited also known as Dhan is only an order collection platform that collects orders on behalf of clients and places them on BSE StarMF for execution. Client expressly agrees that Dhan is not liable or responsible and does not represent or warrant any damages regarding non- execution of orders or any incorrect execution of orders with regard to the funds chosen by the client or due to, but not being limited to, any link/system failure, delay in transfer of the funds on account of any unforeseen circumstances/issues in the banking system/payment aggregators or any other problems that may result in a delay in crediting the funds into the BSE Star MF's bank account. Raise Securities Private Limited (Dhan) does not engage in proprietary trading on its own account.


Mutual fund investments are subject to market risks, read all scheme related documents carefully before investing. Dhan is not a distributor or agent of any mutual fund. Mutual Funds are not exchange-traded products. Any related disputes will not have access to the Exchange-investor redressal forum or arbitration mechanism. For other disclaimers please refer https://dhan.co/advertisement-disclaimer/


Download client registration documents (Rights & Obligations, Risk Disclosure Document, Do's & Don'ts) in vernacular language: BSE | NSE | MCX


Kindly, read the Advisory Guidelines of BSE | NSE | MCX for investors as prescribed by the exchange with reference to their circular dated 27th August, 2021 regarding investor awareness and safeguarding client's assets


Important Links: SEBI | BSE | NSE | MCX | CDSL | SCORES | ODR Portal | Investor Charter for Stock Brokers | Investor Charter for DP | Investor Charter for Research Analyst | UCC Advisory | e-Voting for Shareholders | NCL Client Collateral details | MCXCCL Client Collateral details

Important Information: Terms of Usage | Disclaimers | Privacy Policy | Grievances | Grievances RA | Risk Management Policy | Risk Disclosure | Advertisement Disclaimer | Referral Terms & Conditions | Saarthi 2.0 Mobile App for Investors | Master Circular for Online Dispute Resolution